VERASTEM INC (VSTM) Stock News
NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
VSTM Latest News, Press Relases and Analysis
What's Going On With Verastem Oncology Stock On Monday?
Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal
Deutsche Bank reaffirmed its Buy rating on Roblox Corporation (NYSE:RBLX) shares on May 19, with a price target of $78. The report followed the announcement of a new partnership between Roblox and Google for Rewarded Video Ads. With plans to scale distribution even further in the near future, Roblox’s partnership with Google will utilize AdMob […]
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology Announces $75 million Private Placement
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
